Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 15;197(8):3260-3270.
doi: 10.4049/jimmunol.1600033. Epub 2016 Sep 19.

Direct IL-6 Signals Maximize Protective Secondary CD4 T Cell Responses against Influenza

Affiliations

Direct IL-6 Signals Maximize Protective Secondary CD4 T Cell Responses against Influenza

Tara M Strutt et al. J Immunol. .

Abstract

Memory T cells can often respond against pathogens that have evaded neutralizing Abs and are thus key to vaccine-induced protection, yet the signals needed to optimize their responses are unclear. In this study, we identify a dramatic and selective requirement for IL-6 to achieve optimal memory CD4 T cell recall following heterosubtypic influenza A virus (IAV) challenge of mice primed previously with wild-type or attenuated IAV strains. Through analysis of endogenous T cell responses and adoptive transfer of IAV-specific memory T cell populations, we find that without IL-6, CD4+, but not CD8+, secondary effector populations expand less and have blunted function and antiviral impact. Early and direct IL-6 signals to memory CD4 T cells are required to program maximal secondary effector responses at the site of infection during heterosubtypic challenge, indicating a novel role for a costimulatory cytokine in recall responses.

PubMed Disclaimer

Figures

Figure 1
Figure 1. High priming doses of IAV are lethal in the absence of IL-6
WT (black symbols) or Il6−/− (grey symbols) mice on a BALB/c background were infected with a low dose (500 EID50 = 0.1 LD50 for WT mice) or high dose (2500 EID50 = 0.5 LD50) of A/PR8 (H1N1). Weight loss following (a) low and (b) high dose challenge (n = 5 mice/group; one of 5 experiments). On the indicated days following 2500 EID50 challenge, (c) survival, and (d) viral titers were assessed (n =3–5 mice/group/day). H&E stained lung sections were scored blindly for levels of histopathology on 7 dpi. Summary of analysis (n = 3–5 mice/group/day) (e), and representative H&E images at 10x (f) for categories of inflammation scored in (e) (PV = peri-vascular; PB = peri-bronchial; AI = alveolar inflammation; IE = Intra-epithelial).
Figure 2
Figure 2. IL-6 is required for optimal heterosubtypic protection
WT or Il6−/− mice on a BALB/c background were primed with a low dose (500 EID50 = 0.1 LD50 for WT mice) of A/PR8 (H1N1). After 45 days mice were challenged with a 150 LD50 dose of A/Philippines (H3N2) virus and (a) morbidity and (b) survival monitored (n=5 mice/group; one of 2 experiments). Viral titers (c) from lungs of A/PR8-primed WT or Il6−/− mice (n=4 mice/group), or unprimed WT control mice (n=3) were assessed on the stated dpi after 150 A/Phil challenge. Data is representative of one of two experiments. The dashed line in (c) represents sensitivity cutoff of the assay.
Figure 3
Figure 3. CD4 but not CD8 T cell cytokine responses are reduced during heterosubtypic challenge of mice primed with attenuated IAV
WT or Il6−/− C57BL/6 mice were primed with two doses of 2500 TCID50 A/Alaska ten days apart. At day 45 post-priming mice were challenged with 20 LD50 A/PR8. Survival and weight loss (a) of primed or unprimed control WT and Il6−/− mice (n=4 mice/group; one of two experiments). IFN-γ responses elicited by immunodominant MHC I-restricted peptides were enumerated by ELISPOT from cells isolated from stated organs 5 days after A/PR8 challenge primed WT or Il6−/− mice (b) and numbers of CD44hi CD8 T cells in the lung determined by FACS (c) (n=3 mice/group; one of two experiments). Similarly, IFN-γ (d) and IL-2 (e) responses were enumerated in stated organs by ELISPOT using IAV lysate to stimulate CD4 T cells (n=3 mice/group; one of two experiments) and the number of CD44hi CD4 T cells in the lung determined by FACS (f). Dual IFN-γ and IL-2 production by CD4 T cells in the stated organs in response to IAV lysate was determined by ICCS and the frequency expressed as a ratio to the WT response (g), representative staining of spleen cells (h), and the enumeration of dual cytokine producing cells (i) is shown.
Figure 4
Figure 4. Memory CD4 T cell formation following IAV priming is not impaired in the absence of IL-6
WT or Il6−/− C57Bl/6 mice were primed with A/Alaska as described in Figure 3. The (a) percentage and (b) absolute number of NP311–325 tetramer+ CD44high CD4 T cells was enumerated at 45 dpi (n=4 mice/group; one of 2 similar experiments). In separate experiments, WT or Il6−/− mice receiving 1×106 Thy-disparate naïve OT-II donor cells were primed with 0.1 LD50 A/PR8-OVAII. At 45 dpi, the (c) percentage and (d) absolute number of donor cells detected in stated organs was determined (n=4 mice/group; one of 2 experiments). The mean fluorescence intensity of CD127 on donor cells was determined by FACS (e). The percentage of donor cells co-producing IFN-γ and IL-2 was determined by intracellular cytokine staining following ex vivo stimulation (f).
Figure 5
Figure 5. Protection mediated by memory CD4+, but not CD8+, T cells is compromised in the absence of IL-6
Memory CD8 T cells, 5×106, generated from HA TcR transgenic cells were transferred to naïve WT or Il6−/− BALB/c mice. Mice were subsequently infected with 10,000 EID50 A/PR8 and their (a) survival and (b) weight loss monitored (n=10 mice/group) and compared to mice not receiving donor memory cells (n=3 mice). WT or Il6−/− BALB/c mice that received 5×106 memory CD4 T cells generated from HNT TcR transgenic cells were challenged with 10,000 EID50 A/PR8, and (c) survival and (d) weight loss monitored. Analysis was also done on mice challenged with 2500 EID50 A/PR8 (e and f) (n=10 mice/group). In separate experiments, WT mice receiving 5×106 memory HNT CD4 T cells were treated with 0.5 mg of IL-6 neutralizing Ab on the stated days post 10,000 EID50 A/PR8 challenge. Control mice were treated with isotype control Ab on 0, 2, 4, 6, and 8 dpi. Survival (g) and weight loss (h) is depicted for 5 mice/group (one of three experiments).
Figure 6
Figure 6. Initial activation of memory CD4 T cells and early viral control are not impacted by IL-6
Unprimed thy-disparate WT or Il6−/− mice received 1×106 CFSE-labeled HNT memory CD4 and were challenge with 10,000 EID50 A/PR8. Representative (a) donor CD69 expression, (b) proliferation profile determined by loss of CFSE label, and (c) cell number at 4 dpi were assessed in stated organs (n=3 mice/group). Results from 1 of 3 similar experiments. In separate experiments, (d) pulmonary viral titers were determined on 4 dpi from lungs of WT BALB/c or Il6−/− mice receiving 5×106 memory HNT cells or not and challenged with 10,000 EID50 A/PR8 (n = 4/group). Results representative of 2 separate experiments.
Figure 7
Figure 7. 2° CD4 T cell effector number and function are reduced in the absence of IL-6
HNT memory cells, 1×106, were transferred to naïve WT BALB/c subsequently infected with 2,500 EID50 A/PR8 and treated with 0.5mg of isotype or IL-6 neutralizing Ab on days 0, 2, 4, and 6 dpi. Donor cells were enumerated at 7 dpi (a). Dual IFN-γ+/IL-2+ cytokine producing cells (b) and mean fluorescence intensity of IFN-γ signal (c) was assessed at 7 dpi by ICCS (n=4 mice/group; representative of 3 similar experiments). Viral titers (d) were determined on 7 dpi in mice receiving donor HNT memory cells followed by 2,500 EID50 A/PR8 challenge (n=4 mice/group; one of two experiments). WT C57Bl/6 mice were primed with A/Alaska, challenged with A/PR8 as described in Figure 3, and mice treated with isotype or IL-6 neutralizing Ab as described above. On 5dpi, NP311–325 tetramer+ CD4 T cells detected in the lung (e) were assessed for dual IFN-γ+/IL-2+ cytokine producing cells. The frequency (f and g) and number (h) is shown (n=4 mice/group; one of 2 similar experiments).
Figure 8
Figure 8. Direct IL-6 signals to memory CD4 T cells maximize2° effector responses
Memory populations were generated in vitro from IL6ra+/+ and Il6ra−/− OT-II cells. Cytokine production (a) from an equal number of IL6ra+/+ and Il6ra−/− memory cells was determined by luminex analysis of supernatants from triplicate wells 8 hours post-stimulation. Results representative of 3 separate experiments. IL6ra+/+ or Il6ra−/− OT-II memory cells, 1×106, were transferred to different Thy-disparate hosts followed by infection with 0.1 LD50 A/PR8-OVAII. At 7 dpi, the total number of donor cells (b) and IFN-γ+ and IL-2+ cytokine production in the lung were determined from 4 mice/group (one of 2 separate experiments). Representative ICCS staining of lung cells in the absence and presence of stimulation is shown in (c) and the percentage of dual IFN-γ+ IL-2+ donor cells in (d). In separate experiments, WT.Thy1.2/Thy1.1 or Il6ra−/−.Thy1.2 OT-II memory cells, 1×106, were co-transferred to the same WT C57BL/6.Thy1.1 host followed by infection with 0.1 LD50 A/PR8-OVAII. At 7 dpi, the total frequency of donor cells (e), the ratio of Il6ra−/− to WT OT-II memory cells (f), and the frequency of CD25+ Foxp3+ CD4+ T cells lymphocytes from the host or donor populations (g and h) was determined from 4 mice/group (one of 2 separate experiments).

Similar articles

Cited by

References

    1. Tan AC, Mifsud EJ, Zeng W, Edenborough K, McVernon J, Brown LE, Jackson DC. Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. Mol Pharm. 2012;9:2710–2718. - PubMed
    1. Lau YF, Tang LH, Ooi EE, Subbarao K. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology. 2010;406:80–87. - PMC - PubMed
    1. Tuvim MJ, Gilbert BE, Dickey BF, Evans SE. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One. 2012;7:e30596. - PMC - PubMed
    1. Shinya K, Okamura T, Sueta S, Kasai N, Tanaka M, Ginting TE, Makino A, Eisfeld AJ, Kawaoka Y. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. Virol J. 2011;8:97. - PMC - PubMed
    1. Norton EB, Clements JD, Voss TG, Cardenas-Freytag L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol. 2010;84:2983–2995. - PMC - PubMed

Publication types